CD36 and ovarian cancer: The authors of this study demonstrated that the prosaposin-based therapeutic agent inhibits the progression of ovarian cancer through TSP-1 and downstream CD36 signaling, which further highlights the importance of CD36 in the tumor microenvironment 81.